SAVOR: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus. A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial To Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stoke in Patients with Type 2 Diabetes


Total Award Amount

  • 159996.00
  • Direct Costs

  • 126978.00
  • Sponsor Award Id

  • D168OC00003
  • Contributor

  • William Rogers   Principal Investigator